We claim:

1. A compound of the formula I



I

wherein

R1, R2 are each independently H, F, Cl, Br, $(C_1\text{-}C_6)$-alkyl, CF_3, OCF_3, NO_2, CN, O-$(C_1\text{-}C_6)$-alkyl, COO$(C_1\text{-}C_6)$-alkyl, COOH, CO-$(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-COOH, $(C_0\text{-}C_6)$-alkyl -COO$(C_1\text{-}C_6)$-alkyl or SO_2-$(C_1\text{-}C_6)$-alkyl;

R3 is OH, $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-aryl, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_2\text{-}C_6)$-alkenyl or O-$(C_2\text{-}C_6)$-alkynyl, wherein said $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-aryl, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_2\text{-}C_6)$-alkenyl and O-$(C_2\text{-}C_6)$-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O-$(C_1\text{-}C_6)$-alkyl, NH_2, NH$(C_1\text{-}C_6)$-alkyl or N$((C_1\text{-}C_6)\text{-alkyl})_2$;

A, B, D and E are each independently CH or N, with the proviso that at least one of groups A, B, D and E is N;

m is 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 wherein:

R1, R2 are each independently H, F, Cl, Br, $(C_1\text{-}C_6)$-alkyl, CF_3, OCF_3, NO_2, CN, O-$(C_1\text{-}C_6)$-alkyl, $COO(C_1\text{-}C_6)$-alkyl, COOH, CO-$(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-COOH, $(C_0\text{-}C_6)$-alkyl-$COO(C_1\text{-}C_6)$-alkyl or SO_2-$(C_1\text{-}C_6)$-alkyl;

R3 is OH, $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-aryl, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_2\text{-}C_6)$-alkenyl or O-$(C_2\text{-}C_6)$-alkynyl, wherein said $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-aryl, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_2\text{-}C_6)$-alkenyl and O-$(C_2\text{-}C_6)$-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O-$(C_1\text{-}C_6)$-alkyl, NH_2, $NH(C_1\text{-}C_6)$-alkyl or $N((C_1\text{-}C_6)\text{-alkyl})_2$;

A, B, D and E are each independently CH or N, with the proviso that at least one of groups A, B, D and E is N;

m is 1 or 2;

and pharmaceutically acceptable salts thereof.

3. The compound of Claim 2 wherein:

R1 is H or F;

R2 is each independently H, F, Cl, Br, $(C_1\text{-}C_6)$-alkyl, CF_3, OCF_3, O-$(C_1\text{-}C_6)$-alkyl, $COO(C_1\text{-}C_6)$-alkyl, COOH, CO-$(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-COOH, $(C_0\text{-}C_6)$-alkyl-$COO(C_1\text{-}C_6)$-alkyl or SO_2-$(C_1\text{-}C_6)$-alkyl;

R3 is OH, $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-aryl, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_2\text{-}C_6)$-alkenyl or O-$(C_2\text{-}C_6)$-alkynyl, wherein said $(C_1\text{-}C_6)$-alkyl, $(C_0\text{-}C_6)$-alkyl-aryl, O-$(C_1\text{-}C_6)$-alkyl, O-$(C_2\text{-}C_6)$-alkenyl and O-$(C_2\text{-}C_6)$-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O-$(C_1\text{-}C_6)$-alkyl, NH_2, $NH(C_1\text{-}C_6)$-alkyl or $N((C_1\text{-}C_6)\text{-alkyl})_2$;

A is N;

B, D, E are each CH;

m is 1 or 2;

and pharmaceutically acceptable salts thereof.

4. The compound of Claim 3 wherein:

R1 is H or F;

R2 is H, Cl, $(C_1$-$C_6)$-alkyl, CF_3, $COO(C_1$-$C_6)$-alkyl or COOH,

R3 is H or phenyl;

X is OH, O-$(C_1$-$C_6)$-alkyl, NH_2, $NH(C_1$-$C_6)$-alkyl or $N((C_1$-$C_6)$-alkyl$)_2$;

A is N;

B, D, E are each CH;

m is 2;

and pharmaceutically acceptable salts thereof.

5. A pharmaceutical composition comprising one or more compounds of Claim 1 and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of Claim 5 comprising at least one additional active ingredient.

7. The pharmaceutical composition of Claim 6 wherein said additional active ingredient is selected from the group consisting of:

antidiabetics, hypoglycemic active ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients acting on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-β agonists or amphetamines.

8. A method of reducing blood sugar comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

9. A method of treating type II diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

10. A method of treating treating lipid and carbohydrate metabolism disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

11. A method of treating arteriosclerotic symptoms comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

12. A method of treating insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

13. A process of preparing a compound of Claim 1, which comprises reacting ureas of the formula 2 with reactive acid derivatives of formula 4 selected from the group comprising acid chlorides and anhydrides:



2



4

wherein R1, R2, R3, A, B, D and E are as defined in claim 1 and Y is selected from the group comprising Cl or



wherein R1 is as defined above.

14. A process of preparing a compound of Claim 1, which comprises reacting an aniline derivative of the formula 3 with an aroyl isocyanate of the formula 4



3



4

wherein R1, R2, R3, A, B, D and E are each as defined in Claim 1 and Y is NCO.